# R1 Clinical-Safety Review — gallbladder_cancer

VERDICT: APPROVE

Adversarial verdict file (.verdict.md): NOT PRESENT — reviewed sidecar directly.
Goldens changed: no (documentation/KB narrative, not engine logic).

## 1. SAFETY — pass
No unsafe, misleading, or absolute directive statements. Framing is decision-support:
"can be considered", "reasonable", "individualized decision with MDT". Correctly states
surgery is the only potentially curative option, correctly lists contraindications
(distant mets, major portal vein/hepatic artery involvement, nodal spread beyond the
hepatoduodenal ligament), and correctly warns against tumor seeding with laparoscopic
excision when GBC is suspected preop. Palliative-scope statement (no bypass/metastasectomy)
is appropriate and not harmful.

## 2. GROUNDING — pass, consistent with DeVita/NCCN standard of care
- Stage-driven resectability, incidental-post-cholecystectomy re-resection, open over
  laparoscopic when suspected, extended resection for serosal/hepatic extension —
  all standard and DeVita-consistent.
- Adjuvant fluoropyrimidine-based therapy extrapolated from biliary-tract-cancer data
  (BILCAP/capecitabine lineage) — correctly hedged as extrapolation, not GBC-specific RCT.
- First-line gem + platinum doublet (ABC-02 lineage) and second-line oxaliplatin/FOLFOX-type
  (ABC-06 lineage) — correctly characterized, no fabrication.
- HER2 amplification signal, FGFR2/IDH1 being cholangio- more than GBC-validated — accurate
  and appropriately labeled "emerging / trial-directed, not settled standard."
No claim is mis-attributed; the doc even carries an explicit "What DeVita does not resolve"
section. No fabricated or outdated regimen.

## 3. DOSE-FREE — pass
No mg, mg/m2, AUC, or numbered schedules. "12th ed", "stage I–IV", "CA 19-9", "CEA" are
edition/stage/biomarker labels, not doses. Confirmed dose-free.

## 4. SCOPE — pass
Consistently hedged; repeatedly defers to hepatobiliary MDT/tumor board and clinical trials;
no directive overreach.

## 5. ADVERSARIAL FLAGS — none to carry (no verdict file existed).

## Advisory (non-blocking)
- Lines 29-31 (T1 "mucosa or muscular layer ... cholecystectomy alone can be curative"):
  T1a is uncontroversial; T1b radical vs simple cholecystectomy is debated, with many
  centers favoring extended resection for T1b due to nodal risk. The "can be curative" +
  "negative margins" hedging keeps it safe, but consider clarifying the T1a/T1b distinction
  to reduce any undertreatment read. Advisory only.
- Consider a one-line note that recent BTC first-line practice may add immunotherapy to the
  gem/platinum backbone (regimen-agnostic, dose-free) — omission is not unsafe.
